MM
Mark Anthony McCamish
Director

Mark Anthony McCamish insider trades: Avadel Pharmaceuticals (AVDL) stock buys and sales

Director, Avadel Pharmaceuticals Last trade Dec 28, 2023 36 Form 4 filings
$0
Sold, last 12 months
0 sales
$0
Bought, last 12 months
0 buys
12
Open-market trades
since 2018
6
Companies
last trade 2023

Trades on the price chart

Daily close, with an arrow on each day they bought or sold

Companies

Where Mark reports to the SEC

Open-market buys and sales

12 trades reported on SEC Form 4, newest first

DateStockTypeValue
Dec 28, 2023AVDL↓ Sell$1.1M
Aug 11, 2023AVDL↓ Sell$433K
Sep 17, 2020AVDL↑ Buy$985K
Apr 1, 2020FTSV↓ Sell$3.1M
Jun 25, 2019FTSV↓ Sell$90K
Jun 20, 2019FTSV↓ Sell$92K
May 20, 2019FTSV↓ Sell$200K
Apr 18, 2019FTSV↓ Sell$299K
Mar 19, 2019FTSV↓ Sell$299K
Feb 20, 2019FTSV↓ Sell$247K
Jan 18, 2019FTSV↓ Sell$292K
Dec 26, 2018FTSV↓ Sell$191K

Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.

Other AVDL insiders

Open-market trades in the last 12 months

About Mark Anthony McCamish's insider trades

Mark Anthony McCamish is a director at Avadel Pharmaceuticals (AVDL). Since Dec 26, 2018, Mark has reported 1 open-market purchase worth $985K and 11 sales worth $6.3M on SEC Form 4. There have been no open-market trades in the last 12 months.

Their filings also include grants and awards (18 filings), option exercises (10 filings), shares returned to the company (2 filings), gifts (2 filings). These aren't open-market trades and aren't counted above.

How to read insider trades

Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every AVDL insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.